Lipocine (LPCN) Status Update summary

Obesity treatment landscape and unmet needs

• Obesity is a global health crisis, projected to affect 1 billion people by 2030, with significant comorbidities and healthcare costs.

• Current therapies like GLP-1 agonists achieve significant weight loss but are limited by loss of lean mass, bone density, tolerability, and rapid weight regain after discontinuation.

• BMI is insufficient for assessing obesity-related health risk; more precise body composition measures are needed.

• There is a critical need for treatments that reduce fat while preserving or increasing muscle and bone mass.

LPCN2401 mechanism and formulation

• LPCN2401 is a proprietary oral androgen receptor agonist (testosterone esters) designed for once-daily dosing, with strong patent protection.

• Mechanisms include inducing lipolysis, reducing lipogenesis, inhibiting adipocytokines, stimulating muscle growth, and promoting bone formation.

• Lip'ral-based formulation enhances oral bioavailability and enables efficient delivery of lipophilic actives, potentially improving compliance.

• The formulation can be co-administered with vitamin E, which may amplify benefits and improve oral absorption.

Clinical results and body composition effects

• In a 36-week, placebo-controlled Phase II trial (n=56), LPCN2401 and LPCN2401+E improved body composition by reducing fat mass, increasing lean mass, and improving bone mineral content compared to placebo.

• Functional improvements included increased hand grip strength and favorable changes in walk time.

• Liver health markers improved, with reductions in ALT, AST, ALP, GGT, and liver fat, and higher rates of NASH resolution without fibrosis worsening.

• Both formulations were weight neutral over 36 weeks, with trends toward weight reduction in longer-term extension.